European Academy of Allergy and Clinical Immunology (EAACI) 2021

The effect of tezepelumab in patients with allergic and non-allergic asthma: results from the NAVIGATOR phase 3 study

Efficacy of tezepelumab in patients with perennial allergic asthma: results from the NAVIGATOR phase 3 study

The effect of tezepelumab in patients with severe, uncontrolled asthma and comorbid atopic dermatitis: results from the NAVIGATOR phase 3 study

Efficacy of tezepelumab in patients with severe, uncontrolled asthma, according to baseline blood eosinophil count and allergic status: results from the phase 3 NAVIGATOR study

Efficacy of benralizumab in atopic and non-atopic severe eosinophilic asthma patients: post-hoc analysis from the Italian ANANKE real-life study

Efficacy and Safety of Benralizumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Results from the Phase III OSTRO Trial

Comparison of patient outcomes and eosinophil levels in patients with eosinophilic immune dysfunction–related inflammatory diseases using a large US electronic health record real-world database

REal world inVestigation of Eosinophilic-Associated disease overLap (REVEAL)

Use of short-acting beta-2 agonists (SABA) and exacerbations in children and adolescents - a nationwide Swedish asthma cohort (HERA)

Short-Acting β2-Agonist Prescription Patterns in Patients with Asthma in Turkey: Results from SABINA III

Mapping the cytokine and clinical responses to nasal allergen challenge in birch pollen allergic individuals